Novartis Europharm withdraws EMA application

Monday 19 April 2010

The European Medicines Agency said that Novartis Europharm Ltd has withdrawn its marketing authorisation application for a drug to treat chronic hepatitis C virus infection. The product is Joulferon (albinterferon alpha-2b).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom